How was the role of patients conceived in the processes of generating new therapies, and what was envisioned for the future of patient associations? When and where was their contribution needed? What should institutions and other stakeholders have done to respond to patients’ requests?
These were the main topics tackled during the conference “Active participation of patients in new therapy generation processes: development, evaluation and real access to needed therapies.”
The conference was organized by SIAR (Italian Society on Regulatory Activities), in collaboration with Fondazione per la Ricerca Farmacologica Gianni Benzi and Cittadinanzattiva, and was held on July 10 in Rome, at the Italian Ministry of Health.
The event represented an opportunity to meet, reflect, and analyze the contribution of patient associations to the development of new therapies, in order to define a common path toward greater integration among the various actors involved around the central figure of the patient.
Prof. Adriana Ceci, President of Fondazione Gianni Benzi, opened the conference together with Stefano Vella (President of AIFA), Enrico Bosone (President of SIAR), and Tonino Aceti (President of Cittadinanzattiva).
Prof. Adriana Ceci also moderated the roundtable discussion dedicated to exploring when and where patient associations should contribute to the process of developing new therapies.